Navidea Biopharmaceuticals Announces SNMMI Press Release and Recognition of Phase 1/2 Study Results Jun 24, 2019
Navidea Biopharmaceuticals Announces Day and Time of SNMMI Presentation of Phase 1/2 Study Results and Enrollment Update on its Phase 2B Study Jun 17, 2019
Navidea Biopharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update May 1, 2019
Navidea Biopharmaceuticals Announces Comparative Study to Evaluate the Potential Utility of Tilmanocept In Patients with Tuberculosis (“TB”) Apr 26, 2019
